Category: Abiomed Inc.
An initiative to match veterans with career opportunities in the medical device industry, the Medical Technology Veterans Program, expands its footprint online.
The push to unite military veterans with good jobs in the medical device industry is going online with a new portal designed to connect vets with career mentors from medtech.
Massachusetts medical device maker Abiomed lands reimbursement coding and payment for its Impella heart pump from regulators in the Netherlands.
Abiomed (NSDQ:ABMD) today announced that its Impella technology won reimbursement coding and payment from healthcare regulators in the Netherlands.
The Danvers, Mass.-based medical device company called the win a "significant milestone" for its flagship Impella device, which the company calls the "world's smallest heart pump."
Abiomed CEO Michael Minogue says the company expects to file for pre-market approval from the FDA by the end of fiscal 2014, stressing that it's "business as usual" until then.
Abiomed (NSDQ:ABMD) shares continued their rebound today from a plunge begun late last year after news broke of a federal investigation and new FDA requirements for its flagship Impella heart pump.
Shares of Abiomed gain nearly 7% as investors react to Wall-Street-beating earnings and more than 900% bottom-line growth for the medical device company's fiscal 2013.
Abiomed (NSDQ:ABMD) shares gained nearly 7% this morning after the medical device company reported profit growth in excess of 900%, beating Wall Street's earnings expectations along the way.
The Danvers, Mass.-based heart pump maker reported fiscal 2013 profits of $15.0 million, or 38¢ per share, on sales of $157.6 million, for a whopping bottom-line gain of 904.3% on top-line growth of 25.8%.
Abiomed's Impella heart pumps improve patients' quality of life and costs well below the national standard for cost-effective therapies, according to the company.
Heart support technologies maker Abiomed (NSDQ:ABMD) announced that its Impella heart pump cheaply and effectively improved patients' quality of life, costing less than $39,500 per quality-of-life-year (QALY) gained for high-risk heart failure patients.
Abiomed's preliminary sales report for fiscal Q4 and 2013 details double-digit growth, sending shares up nearly 9% on Wall Street yesterday.
Abiomed (NSDQ:ABMD) shares jumped nearly 9% yesterday after the medical device company reported double-digit sales growth during its fiscal 4th quarter and 2013.
Danvers, Mass.-based Abiomed said preliminary sales for the 3 months ended March 31 were $43.7 million, up 17% over the $37.3 million posted during Q4 2012.
Full-year sales rose 25% to $157.1 million, compared with $126.4 million during fiscal 2012, according to a press release.
Abiomed shares slid 4% yesterday but are clawing their way back this morning after analysts at Piper Jaffray downgraded their rating on the medical device company.
Abiomed (NSDQ:ABMD) shares clawed back some of the nearly 4% lost yesterday as investors reacted to a downgrade by analysts at Piper Jaffray.
The Danvers, Mass.-based medical device company's stock fell from a $17.20-per-share close April 8 to end yesterday at $16.52 per share, a more than 3.9% decline. ABMD shares were trading at $16.98 apiece as of about 11 this morning, however, up 2.8%.